The field of antibody-drug conjugates (ADCs) is entering an exciting era, and there is no shortage of writing today about where this modality is headed: new and novel platforms, next‑generation payloads, and high‑profile acquisitions are all fuelling headlines about future promise. However, what is also truly fascinating about the ADC story is not just “what comes next?” but how ADCs managed to shift from a high‑risk, niche treatment to a powerful therapeutic class in the first place. Drawing on The Tipping Point by Malcolm Gladwell, this article steps back from the current excitement to ask a simpler question: what was the inflection point that finally aligned the right pieces and gave ADCs their momentum?
As the tagline of The Tipping Point suggests, small, often overlooked events can drive much larger shifts in momentum. The expression “big doors swing on little hinges” comes to mind. In Gladwell’s examples, from Sesame Street to the unexpected resurgence of Hush Puppies, these inflection points were driven by the amplifying influence of social connectors [1]. I’d argue that much of the recent success of ADCs can also be traced back to connectors, albeit in a more literal sense.
Early Antibody‑Drug Conjugate Development and First‑Generation Challenges
ADC clinical development has been underway for several decades, with first-in-human trials dating back to the 1980s [8]. Even so, the ADC market remained in its infancy for many decades. The first ADC to receive FDA approval, in 2000, was the first-generation ADC Mylotarg (gemtuzumab ozogamicin), a CD33-targeting ADC approved for CD33-positive acute myeloid leukaemia in older patients with limited treatment options [9,11]. Expectations were high for this first-generation “magic bullet,” but the accelerated approval proved premature: although early studies were promising, confirmatory studies failed to show a benefit over standard therapy at the selected dosing regimen and reported increased treatment-related mortality. Mylotarg was later voluntarily withdrawn from the market, but reintroduced in 2017 for a broader indication and under a revised fractionated dosing regimen.[11].
As CD33 is also expressed on healthy cells, its selection as a target contributed to toxicity, as is the case with many CD33-targeting therapeutics. But the more fundamental issue was structural: Mylotarg couples a cytotoxic payload to a CD33-targeting IgG4 antibody via an acid-cleavable linker. The conjugate was intended to remain intact in circulation and release the payload only after cellular internalisation and lysosomal processing. In practice, the first-generation construct lacked sufficient plasma stability, and its high, heterogeneous payload and aggressive dosing schedule drove off-target exposure, contributing heavily to the drug’s toxicity profile [3]. Mylotarg’s clinical setbacks epitomised the challenges ADCs were experiencing at the time and contributed to a period of caution around the field, as ADCs came to be viewed as technically demanding, high-risk therapeutics.
Second‑Generation Antibody‑Drug Conjugates and Linker Innovation
Even so, a small number of companies, such as Seagen and ImmunoGen, continued to develop next-generation payloads, refine conjugation strategies and linker chemistry, and build proprietary platforms that paved the way for improved ADCs. In 2011, the second generation of ADCs took to the stage with the arrival of the second FDA-approved ADC, Adcetris, which was approved for treatment of relapsed/refractory Hodgkin’s lymphoma and anaplastic large cell lymphoma, followed by Kadcycla, an ADC for solid tumours, which would become the first true commercial blockbuster in its class.
During Kadcyla’s development, several alternative cleavable linkers were tested, along with a non-cleavable version, which was added as a negative control. Surprisingly, the non-cleavable construct not only showed superior plasma stability and a favourable toxicity but also outperformed its cleavable counterparts in antitumor efficacy. Kadcyla was later confirmed in metastatic and adjuvant HER2-positive breast cancer, helping establish ADCs as a credible therapeutic class [3-6].
Antibody‑Drug Conjugates Enter Solid Tumours
The move into solid tumours was just as significant, as most ADC targets up to that point had been in hematologic cancers, which, although clinically important, account for less than 10% of cancer cases globally [12]. Solid tumours also introduced a new set of challenges, including receptor saturation, tissue penetration, and the need to balance efficacy against toxicity. The unexpected success of Kadcyla, which went on to become a standard of care, helped overturn earlier assumptions about ADC design and renewed interest in the class as a whole.
This success paved the way for next-generation ADCs, such as Padcev, Trodelvy and most notably Enhertu, the trastuzumab-based successor to Kadcyla. Leveraging third-generation ADC design features, especially site-directed conjugation, more stable cleavable linkers and higher drug-to-antibody ratios, Enhertu achieved a rare combination of strong tolerability and potent antitumor activity.
ADC Market Growth and the Modern Tipping Point
Between 2017 and 2024, the ADC market expanded rapidly, growing from about $1.6 billion to $13.6 billion at a compound annual growth rate of 35.8%. Enhertu has emerged as the leading product in the class, with projected sales of around $14.3 billion by 2031 [2]. This growth reflects more than commercial momentum: the market’s rapid expansion has been driven by an accelerating wave of approvals, showing that ADCs are no longer defined by a few outliers but have instead entered the mainstream of oncology therapeutics.
Why Antibody‑Drug Conjugates Reached a Tipping Point
The history of ADCs is best understood not as a smooth progression, but as a field that shifted once the right pieces aligned. What ultimately transformed this therapy was not a full reinvention, but a small design change that altered the trajectory of clinical success. In The Tipping Point, this is the moment when a minor variable tips the system, turning slow progress into rapid and sustained impact.
The change itself may have appeared trivial in isolation, yet its consequences reflected what Gladwell describes as the “Power of Context”: a precise intervention introduced at exactly the right point in a complex biological and translational ecosystem. Once that threshold was crossed, efficacy, adoption, and ultimately patient outcomes advanced with momentum disproportionate to the size of the original modification. Its success, driven in part by the fortunate choice of a non-cleavable linker, reset expectations around toxicity and showed that ADCs could be both clinically meaningful and commercially viable. The broader lesson extends beyond ADCs to emerging therapeutics as a whole: when innovation and timing align, a single well-placed adjustment can be enough to redefine the therapeutic landscape.
At Synexa, our ADC solutions combine deep biological insight with robust in vivo models to support confident decision‑making across discovery and development. From target validation to translational pharmacology, we generate high‑quality data that helps teams understand efficacy, safety and differentiation in an increasingly competitive ADC landscape.
References
- Gladwell, M. (2000). The tipping point: How little things can make a big difference. Little, Brown and Company.
- (2026). Comprehensive Review of Historical, Current, and Emerging Antibody-Drug Conjugate Therapies (Report Code GDHCHT661). GlobalData.
- Joubert, N., Beck, A., Dumontet, C., & Denevault-Sabourin, C. (2020). Antibody-drug conjugates: The last decade. Pharmaceuticals (Basel), 13(9), 245. https://doi.org/10.3390/ph13090245
- Krop, I. (2025, January 28, 08:20). The Evolution of Antibody-Drug Conjugates in Oncology: Have we found our “Magic Bullet”? [Video]. Yale Cancer Center Grand Rounds, Yale Cancer Center.
https://youtu.be/zAEV8gtw318?si=aWhMeEr7L-d8gAKP - Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., et al. (2008). Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Research, 68(22), 9280–9290.
- Lewis Phillips, G. (2020, November 6, 14:00). Part 11 – Evolution of Antibody Drug conjugates in cancer – Dr. Gail Phillips, USA [Video]. MICE IDEAS Pvt. Ltd. YouTube. https://youtu.be/scMMHcJ9xx0?si=Kq_ti05qzJYbi3gc
- Peddi, P. F., & Hurvitz, S. A. (2014). Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: Latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 6(5), 202–209. https://doi.org/10.1177/1758834014539183
- Pettinato, M. C. (2021). Introduction to antibody-drug conjugates. Antibodies (Basel), 10(4), 42.
- (2025). Recent Advances in Antibody-Drug Conjugates. NJ Bio, Inc. (December 2025).
- Rubahamya, B., Dong, S., & Thurber, G. M. (2024). Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data. Science Advances, 10(22), eadk1894. https://doi.org/10.1126/sciadv.adk1894
- Selby, C., Yacko, L. R., & Glode, A. E. (2019). Gemtuzumab ozogamicin: Back again. Journal of the Advanced Practitioner in Oncology, 10(1), 68–82.
- Hungria, V. T. M., Chiattone, C., Pavlovsky, M., et al. (2019). Epidemiology of hematologic malignancies in real-world settings: Findings from the Hemato-Oncology Latin America observational registry study. Journal of Global Oncology, 5, 1–19. https://doi.org/10.1200/JGO.19.00025
FAQs on Antibody‑Drug Conjugates
What are Antibody‑Drug Conjugates (ADCs)?
ADCs are targeted cancer therapies that combine a monoclonal antibody with a cytotoxic payload via a chemical linker.
Why did early Antibody‑Drug Conjugates fail?
Early ADCs suffered from unstable linkers, suboptimal target selection, and dosing strategies that led to off‑target toxicity.
What defines next‑generation ADCs?
Next‑generation Antibody‑Drug Conjugates feature improved linker stability, site‑specific conjugation, and optimised drug‑to‑antibody ratios.
What are some examples of Antibody‑Drug Conjugates (ADCs)?
Several Antibody‑Drug Conjugates are approved for clinical use, particularly in oncology. Examples include Mylotarg for acute myeloid leukaemia, Adcetris for lymphomas, Kadcyla and Enhertu for HER2‑positive breast cancer, Trodelvy for breast and urothelial cancers, and Padcev for bladder cancer. These drugs highlight the diversity of targets and tumour types addressed by ADCs.
Are Antibody‑Drug Conjugates used only in cancer and oncology?
Currently, almost all approved Antibody‑Drug Conjugates are used in oncology, where targeted delivery of potent payloads has improved treatment across blood cancers and solid tumours. However, ADC technology is now being explored in early‑stage research for autoimmune and inflammatory diseases, with the aim of improving precision while reducing systemic toxicity.
